Blood eosinophil percentage as a predictor of response to inhaled corticosteroid in bronchiectasis.
bronchiectasis
bronchiectasis exacerbation
eosinophil
inhaled corticosteroid
phenotype
Journal
The clinical respiratory journal
ISSN: 1752-699X
Titre abrégé: Clin Respir J
Pays: England
ID NLM: 101315570
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
revised:
16
04
2023
received:
16
01
2023
accepted:
18
04
2023
medline:
15
6
2023
pubmed:
15
5
2023
entrez:
15
5
2023
Statut:
ppublish
Résumé
The role of inhaled corticosteroid (ICS) among patients with bronchiectasis remains controversial. There is limited evidence of using baseline eosinophil count (absolute and percentage) as a marker to predict the role of ICS among patients with bronchiectasis. A retrospective case-control study was conducted in a major regional hospital and tertiary respiratory referral centre in Hong Kong, including 140 Chinese patients with noncystic fibrosis (CF) bronchiectasis, to investigate the exacerbation risks of bronchiectasis among ICS users and nonusers with different baseline eosinophil counts. ICS user had significantly lower risk to develop bronchiectasis exacerbation with adjusted odds ratio (OR) of 0.461 (95% confidence interval [CI] 0.225-0.945, p-value 0.035). Univariate logistic regression was performed for different cut-offs of blood eosinophil count (by percentage) from 2% to 4% (with a 0.5% grid each time). Baseline eosinophil 3.5% was found to be the best cut-off among all with adjusted OR of 0.138 (95% CI = 0.023-0.822, p-value = 0.030). Baseline eosinophil count of 3.5% might serve as a marker to predict the benefits of ICS on exacerbation risk among patients with non-CF bronchiectasis.
Identifiants
pubmed: 37186375
doi: 10.1111/crj.13624
pmc: PMC10265148
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
548-555Informations de copyright
© 2023 The Authors. The Clinical Respiratory Journal published by John Wiley & Sons Ltd.
Références
Eur Respir J. 2020 Aug 20;56(2):
pubmed: 32398295
Lancet Respir Med. 2016 May;4(5):390-8
pubmed: 27066739
Eur Respir J. 2017 Sep 9;50(3):
pubmed: 28889110
Cytokine. 2017 Nov;99:281-286
pubmed: 28863927
Lancet Respir Med. 2022 Mar;10(3):298-306
pubmed: 34570994
Eur Respir J. 2014 Feb;43(2):343-73
pubmed: 24337046
Lancet Respir Med. 2016 Sep;4(9):731-741
pubmed: 27460163
Cochrane Database Syst Rev. 2018 May 16;5:CD000996
pubmed: 29766487
Ann Am Thorac Soc. 2018 Oct;15(10):1169-1176
pubmed: 30213194
Respir Med. 2006 Sep;100(9):1623-32
pubmed: 16434174
J Clin Med. 2023 Jan 03;12(1):
pubmed: 36615179
Am J Respir Crit Care Med. 2010 Feb 15;181(4):315-23
pubmed: 19892860
Am J Respir Crit Care Med. 2022 Apr 15;205(8):894-902
pubmed: 35050830
J Asthma Allergy. 2021 Nov 30;14:1441-1452
pubmed: 34880630
J Allergy Clin Immunol. 2014 Nov;134(5):1043-50
pubmed: 24985405
J Clin Med. 2022 Aug 11;11(16):
pubmed: 36012941
Am J Respir Crit Care Med. 1998 Sep;158(3):723-7
pubmed: 9730996
Int J Environ Res Public Health. 2021 Aug 10;18(16):
pubmed: 34444179
Am J Respir Crit Care Med. 2017 Nov 1;196(9):1219-1221
pubmed: 28306321
Med J Aust. 2010 Sep 20;193(6):356-65
pubmed: 20854242
Respir Med. 2020 Oct;172:106127
pubmed: 32905889
Respir Med. 1992 Mar;86(2):121-4
pubmed: 1615177
Eur Respir J. 2017 Jun 8;49(6):
pubmed: 28596426
Respir Med. 2021 Aug-Sep;185:106491
pubmed: 34098492
Eur Respir J. 2020 Sep 3;56(3):
pubmed: 32883760
Thorax. 2005 Mar;60(3):239-43
pubmed: 15741443
Clin Respir J. 2023 Jun;17(6):548-555
pubmed: 37186375
PLoS One. 2014 Jul 24;9(7):e102987
pubmed: 25058007
Int J Chron Obstruct Pulmon Dis. 2021 Jul 16;16:2119-2127
pubmed: 34295156